A.D.A.M. Innovations and SOPHiA GENETICS Unite to Revolutionize Liquid Biopsy Testing in Japan

A.D.A.M. Innovations and SOPHiA GENETICS Collaboration: Advancing Liquid Biopsy in Japan

In a groundbreaking partnership announced at the ESMO Congress 2025, A.D.A.M. Innovations, a leading private genetic testing firm in Japan, has teamed up with SOPHiA GENETICS, a prominent global player in AI-driven medical technology. This alliance is set to significantly enhance liquid biopsy testing and companion diagnostics tailored for personalized cancer care in Japan.

A.P. Leading the Charge in Genetic Testing

A.D.A.M. Innovations boasts a rich history in the genetic testing landscape of Japan, having performed over 2.8 million genomic tests over the past two decades. With its high-throughput laboratory strategically positioned in central Tokyo, the company has paved the way for advanced genomics and personalized healthcare, establishing itself as a trusted name in the field.

The collaboration with SOPHiA GENETICS marks a pivotal moment in their journey. By integrating the AI-powered SOPHiA DDM™ platform, A.D.A.M. Innovations is set to elevate its offerings within the realm of precision oncology, enabling more patients to benefit from innovative diagnostic solutions.

The Role of AI in Liquid Biopsy

One of the central focuses of this partnership is the introduction of the MSK-ACCESS® liquid biopsy application, which utilizes sophisticated AI algorithms to analyze circulating tumor DNA (ctDNA) from a single blood draw. This application aims to detect critical genomic alterations with heightened accuracy by employing a matched tumor-normal approach, substantially minimizing the risk of false positives.

This cutting-edge method provides a less invasive option for patients, aligning with modern trends in cancer diagnosis and management. By localizing the testing process and processing samples internally, A.D.A.M. Innovations is poised to enhance turnaround times and reduce costs, thereby advancing local cancer research and patient care.

Development of Companion Diagnostic Tests

In addition to launching the liquid biopsy application, the companies plan to collaborate on a liquid biopsy companion diagnostic (CDx) test in Japan. This aims to democratize access to high-quality tumor profiling for a broader patient population, ultimately improving personalized healthcare delivery. Such developments will also provide significant advantages for pharmaceutical partners, who will gain an essential tool to streamline drug development and market access domestically.

“Our strategic partnership is about making precision oncology more accessible,” stated Ross Muken, President of SOPHiA GENETICS. Muken emphasized the strength of A.D.A.M. Innovations’ clinical background and local market presence, which combined with the robust capabilities of the SOPHiA platform, can effectively push forward the adoption of data-driven medicine in Japan.

Michel Mommejat, President of A.D.A.M. Innovations, reiterated the transformative potential this partnership holds for advancing precision oncology. “Our collaboration is a significant leap towards enhancing patient care and fostering global deployments of companion diagnostics through high-quality, local genomic testing,” he commented.

The announcement at ESMO Congress 2025 reinforces the commitment of both organizations to innovate within cancer care, supporting precision testing and treatments powered by real-time data insights. The excitement surrounding these advancements indicates a promising outlook for oncology patients in Japan, as healthcare continues to evolve with technology at its forefront.

Visit Us at ESMO

For those attending the ESMO Congress 2025 in Berlin from October 17-21, engagement with both A.D.A.M. Innovations and SOPHiA GENETICS is encouraged at booth #2039. Participants can learn more about how these innovations are shaping the future of oncology in Japan and beyond.

For further information on SOPHiA GENETICS, please visit SOPHiAGENETICS.COM or connect on LinkedIn. To explore more about A.D.A.M. Innovations, visit ADAM-INNOVATIONS.COM or follow on LinkedIn.

This collaboration between A.D.A.M. Innovations and SOPHiA GENETICS is a testament to the potential of merging cutting-edge technology with patient-centered care, promising an era where precision oncology is not just a possibility but a reality for many.